Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.41 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.41 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29873645 | 0.95 | MAPT (0.45) | MAPTSLC5A1SLC5A2POLBTP53 | |
| SCHEMBL23354720 | 0.86 | MLYCD (0.47) | MAPTPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL23354751 | 0.86 | PDE4D (0.54) | MAPTPOLBTP53SMN1; SMN2 | |
| SCHEMBL23354760 | 0.84 | GABRA2 (0.54) | MAPTSLC5A1SLC5A2POLBTP53 | |
| SCHEMBL11381170 | 0.84 | ALDH1A1 (0.52) | MAPTPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL15577193 | 0.83 | TP53 (0.46) | MAPTTP53L3MBTL1SMN1; SMN2CNR1 | |
| SCHEMBL23367410 | 0.83 | CA12 (0.49) | MAPTSMN1; SMN2 | |
| SCHEMBL18893766 | 0.82 | DUSP3 (0.46) | MAPTSLC5A1SLC5A2SMN1; SMN2 | |
| SCHEMBL18910060 | 0.82 | CYP1A2 (0.43) | SMN1; SMN2 | |
| SCHEMBL23354755 | 0.82 | GABRA2 (0.54) | MAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-2895478-B1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-9416127-B2 | Triazole carboxamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2895478-A1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-20150191458-A1 | TRIAZOLE CARBOXAMIDES AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| WO-2014041106-A1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191458-A1 | TRIAZOLE CARBOXAMIDES AND USES THEREOF | TAAR1, HCRTR1, TAAR5 | MAPT 545/4885SLC5A1 712/4885SLC5A2 669/4885 |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | MAPT 4378/4885SLC5A1 3482/4885SLC5A2 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.